Evidence map›Paper›PMID 35457187›Full record

ArticleInternational journal of molecular sciences2022

3D Visualization of Human Blood Vascular Networks Using Single-Domain Antibodies Directed against Endothelial Cell-Selective Adhesion Molecule (ESAM).

Nils Rouven Hansmeier, Ina Sophie Büschlen, Rose Yinghan Behncke, Sascha Ulferts, Radjesh Bisoendial, René Hägerling

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Nils Rouven HansmeierResearch Group 'Lymphovascular Medicine and Translational 3D-Histopathology', Institute of Medical and Human Genetics, Charité, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.ORCID 0000-0001-7024-5351
Ina Sophie BüschlenResearch Group 'Lymphovascular Medicine and Translational 3D-Histopathology', Institute of Medical and Human Genetics, Charité, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Rose Yinghan BehnckeResearch Group 'Lymphovascular Medicine and Translational 3D-Histopathology', Institute of Medical and Human Genetics, Charité, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Sascha UlfertsResearch Group 'Lymphovascular Medicine and Translational 3D-Histopathology', Institute of Medical and Human Genetics, Charité, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Radjesh BisoendialDepartment of Rheumatology and Clinical Immunology, Maasstad Hospital, Maasstadweg 21, 3079 DZ Rotterdam, The Netherlands.
René HägerlingResearch Group 'Lymphovascular Medicine and Translational 3D-Histopathology', Institute of Medical and Human Genetics, Charité, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.ORCID 0000-0002-6830-2043
Berlin Institute of Health at Charité - Universitätsmedizin Berlin · DEErasmus MC · NL

Funding

Lipedema Foundation LF#14Lymphatic Malformation Institute 2019-2022
6 · The paper itself

Abstract

High-quality three-dimensional (3D) microscopy allows detailed, unrestricted and non-destructive imaging of entire volumetric tissue specimens and can therefore increase the diagnostic accuracy of histopathological tissue analysis. However, commonly used IgG antibodies are oftentimes not applicable to 3D imaging, due to their relatively large size and consequently inadequate tissue penetration and penetration speed. The lack of suitable reagents for 3D histopathology can be overcome by an emerging class of single-domain antibodies, referred to as nanobodies (Nbs), which can facilitate rapid and superior 2D and 3D histological stainings. Here, we report the generation and experimental validation of Nbs directed against the human endothelial cell-selective adhesion molecule (hESAM), which enables spatial visualization of blood vascular networks in whole-mount 3D imaging. After analysis of Nb binding properties and quality, selected Nb clones were validated in 2D and 3D imaging approaches, demonstrating comparable staining qualities to commercially available hESAM antibodies in 2D, as well as rapid and complete staining of entire specimens in 3D. We propose that the presented hESAM-Nbs can serve as novel blood vessel markers in academic research and can potentially improve 3D histopathological diagnostics of entire human tissue specimens, leading to improved treatment and superior patient outcomes.

Indexed as

Single-Domain AntibodiesEndothelial CellsHumansImaging, Three-DimensionalStaining and LabelingSingle-Domain Antibodies3D microscopy3D reconstructionblood vessel markerESAMhistopathologylight sheet imagingnanobodiessingle-domain antibodies

Identifiers

PMID35457187
PMCPMC9028812
OpenAlexW4223961151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.